Efecto de la suplementación oral con una fórmula que contiene ácido R-lipoico en pacientes con glaucoma

  1. S.M. Sanz-González 1
  2. J. Raga-Cervera 12
  3. M. Aguirre Lipperheide 3
  4. V. Zanón-Moreno 168
  5. V. Chiner 4
  6. A.I. Ramírez 57
  7. M.D. Pinazo-Durán 16
  1. 1 Generalitat Valenciana
    info

    Generalitat Valenciana

    Valencia, España

    ROR https://ror.org/0097mvx21

  2. 2 Hospital de Manises
    info

    Hospital de Manises

    Valencia, España

    ROR https://ror.org/0396mnx76

  3. 3 Nua Biological Innovations S.L., Erandio, Vizcaya, España
  4. 4 Hospital Universitario Doctor Peset
    info

    Hospital Universitario Doctor Peset

    Valencia, España

    ROR https://ror.org/03971n288

  5. 5 Instituto de Salud Carlos III
    info

    Instituto de Salud Carlos III

    Madrid, España

    ROR https://ror.org/00ca2c886

  6. 6 Universitat de València
    info

    Universitat de València

    Valencia, España

    ROR https://ror.org/043nxc105

  7. 7 Universidad Complutense de Madrid
    info

    Universidad Complutense de Madrid

    Madrid, España

    ROR 02p0gd045

  8. 8 Universidad Internacional de Valencia
    info

    Universidad Internacional de Valencia

    Valencia, España

    ROR https://ror.org/00gjj5n39

Revue:
Archivos de la Sociedad Española de Oftalmologia

ISSN: 0365-6691

Année de publication: 2020

Volumen: 95

Número: 3

Pages: 120-129

Type: Article

DOI: 10.1016/J.OFTAL.2019.11.009 DIALNET GOOGLE SCHOLAR

D'autres publications dans: Archivos de la Sociedad Española de Oftalmologia

Résumé

Objective To analyse the safety and effectiveness of the oral administration of a commercialised supplement containing R-alpha lipoic acid, taurine, vitamins C and E, lutein, zeaxanthin, zinc, copper and docosahexaenoic acid, in patients with primary open angle glaucoma (POAG), and in control subjects. Material and methods A prospective study of cases and controls was carried out, including 30 participants of both genders that were divided into: POAG Group (n = 15) and a control group (CG; n = 15), assigned to the oral intake of NuaDHA preparations Vision® (1 pill/day) + NuaDHA 1000 (2 pills/day) for 6 months. Participants were interviewed, ophthalmologically examined, and peripheral blood was taken for routine analysis and the determination of the pro-oxidant (malondialdehyde) and total antioxidant status. Statistical analysis was performed using the SPSS 22.0 program. Results After 6 months of supplementation, there was a significant increase in the plasma total antioxidant status (1.073 ± 0.090 mM vs 1.276 ± 0.107 mM, P = .028), along with a parallel decrease in malondialdehyde (7.066 ± 1.070 μM vs 2.771 ± 0.462 μM, P = .005) in the POAG group. The malondialdehyde also decreased in the control group (6.17 ± 1.336 vs. 2.51 ± 0.391, P = .028). The Schirmer test improved (20-30%) and the subjective dry eye signs/symptoms noticeably decreased in the POAG group versus the CG. Conclusions Formulations containing antioxidant vitamins, R-alpha lipoic acid and docosahexaenoic acid, administered for 6 consecutive months, counteracted the oxidative stress by further stabilising the morphological/functional parameters of both the ocular surface and the glaucoma, without presenting with adverse effects or intolerances.